Last reviewed · How we verify

NCT07101718

Outcomes and Risk Factors for Liver Transplantation Using Significant Fibrotic Grafts

Completed Last updated 3 August 2025
What this trial tests

trial testing No intervention in Liver Transplant in 25,419 participants. Completed in 31 December 2024.

Timeline
1 July 2024
Primary endpoint
10 July 2024
31 December 2024

Quick facts

Lead sponsorZhejiang University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment25,419
Start date1 July 2024
Primary completion10 July 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhejiang University

Who can join

Eligibility, any sex, with Liver Transplant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center study to investigate the impact of fibrotic liver greafts in liver transplant recipient.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Liver Transplant

Currently open trials in the same condition.

Other Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07101718.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing